MIRM / Mirum Pharmaceuticals, Inc. - Документы SEC, Годовой отчет, Доверенное заявление

Security Type

Calculation of Filing Fee Tables S-3 Mirum Pharmaceuticals, Inc. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward

As filed with the Securities and Exchange Commission on August 12, 2025

S-3ASR Table of Contents As filed with the Securities and Exchange Commission on August 12, 2025 Registration No.

MIRUM PHARMACEUTICALS, INC., Dated as of [•], 20__ Debt Securities

EX-4.6 Exhibit 4.6 MIRUM PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1  DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2  ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Cert

MIRUM PHARMACEUTICALS, INC. _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________

EX-4.10 Exhibit 4.10 MIRUM PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF MIRUM PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MIRUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associat

MIRUM PHARMACEUTICALS, INC. _____________, AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF __________

EX-4.9 Exhibit 4.9 MIRUM PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF MIRUM PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MIRUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking association] organi

MIRUM PHARMACEUTICALS, INC. _____________, AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF __________

EX-4.11 Exhibit 4.11 MIRUM PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MIRUM PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between MIRUM PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and [•], a [corporation] [national banking associat

Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update –Second quarter 2025 total revenue of $128 million –2025 revenue guidance increased to $490 to $510 million –Conference call to provide business updates

Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update –Second quarter 2025 total revenue of $128 million –2025 revenue guidance increased to $490 to $510 million –Conference call to provide business updates today, August 6 at 1:30 p.m. PT / 4:30 p.m. ET FOSTER CITY, Calif. – August 6, 2025 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today re

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Mirum Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Mirum Pharmaceutical

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2025 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissio

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commission

Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update –First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million –VISTAS study in PSC expected to complete enrollment

Exhibit 99.1 Mirum Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update –First quarter 2025 total revenue of $111.6 million; 2025 guidance increased to $435 to $450 million –VISTAS study in PSC expected to complete enrollment in third quarter of 2025; topline data expected in second quarter of 2026 –LIVMARLI oral tablet formulation FDA approved –Conference call

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update •2024 net product sales of $336.4 million •2025 expected global net product sales of $420 million to $435 million •VISTAS study of volixibat

Exhibit 99.1 Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update •2024 net product sales of $336.4 million •2025 expected global net product sales of $420 million to $435 million •VISTAS study of volixibat in PSC expected to complete enrollment in second half 2025; topline data expected 2026 •CTEXLI (chenodiol) approved in the US for cerebr

Filing Fee Table

Calculation of Filing Fee Tables S-8 Mirum Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity 2019 Equity Incentive Plan, Common Stock, $0.0001 per share Other 2,416,904 $ 51.47 $ 124,398,048.88 0.00

Mirum Pharmaceuticals, Inc. Insider Trading and Window Period Policy, as amended

Exhibit 19.1 MIRUM PHARMACEUTICALS, INC. INSIDER TRADING AND WINDOW PERIOD POLICY I.Insider Trading Policy A.Persons Covered Part I of this policy applies to all directors, officers, other employees and consultants of Mirum Pharmaceuticals, Inc. (the “Company”) and its subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any fami

As filed with the Securities and Exchange Commission on February 26, 2025

As filed with the Securities and Exchange Commission on February 26, 2025 Registration No.

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2025 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-389

EXHIBIT 1

EX-1 2 ex1.htm EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in

EXHIBIT 1

EXHIBIT 1 WHEREAS, in accordance with Rule 13d-1(k)(1) under the Securities and Exchange Act of 1934 (the "Act"), only one joint Statement and any amendments thereto need to be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act with respect to the same securities, provided that said persons agree in writing that such Statement or amendments thereto is filed on behalf of each of them; NOW, THEREFORE, the parties hereto agree as follows: Eventide Asset Management, LLC, Finny Kuruvilla, M.

Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates –2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate

Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited 2024 Net Product Sales and Cash Balance and Provides Corporate Updates –2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate –2025 expected global net product sales of $420 million to $435 million –VISTAS study of volixibat in primary sclerosing cholangitis exp

J a n u a r y 2 0 2 5 Mirum Pharmaceuticals: Transforming Lives in Rare Disease Exhibit 99.2 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on informat

J a n u a r y 2 0 2 5 Mirum Pharmaceuticals: Transforming Lives in Rare Disease Exhibit 99.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commi

MIRM / Mirum Pharmaceuticals, Inc. / BIOTECHNOLOGY VALUE FUND L P - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment

SC 13G/A 1 sc13ga107422mirm11142024.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 1)1 Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par val

MIRM / Mirum Pharmaceuticals, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment

SC 13G/A 1 eventidemirum-sc13ga.htm SC 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mirum Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) September 30, 2024 (Date of Event which Requires F

Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update •Third quarter global net product sales of $90.3 million, 2024 guidance increased to $330-335 million •Volixibat granted breakthrough therapy designation for treatment of cholestatic pruritus in PBC, interim results to be presented as a Late Breaker presentation at AASLD’s The Liver Meeting

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001

Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.

MIRUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY As Amended April 4, 2024, Effective as of April 4, 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Mirum Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this N

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Mirum Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update •Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million •Positive interim results for v

Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update •Second quarter global net product sales of $77.8 million, on track to achieve full-year guidance of $310 to $320 million •Positive interim results for volixibat in VISTAS PSC and VANTAGE PBC studies •LIVMARLI for treatment of PFIC granted marketing authorization in Europe •Initiating LIVM

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2024 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissi

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2024 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissio

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2024 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissio

Forms of restricted stock unit grant notice and award agreement for non-employee directors electing to defer settlement of restricted stock units under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Registrant’s Quarterly Report on Form 10-Q, as filed with the SEC on May 8, 2024, and incorporated by reference herein).

Deferred Settlement Mirum Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice (2019 Equity Incentive Plan) Mirum Pharmaceuticals, Inc. (the “Company”), pursuant to its 2019 Equity Incentive Plan (the “Plan”), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company’s Common Stock (“Restricted Stock Units”) set forth below (the “Award”). The Award is s

Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update •First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million •FDA approval of LIVMARLI for cholestat

Exhibit 99.1 Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update •First quarter 2024 total revenue of $69.2 million, on track to achieve full-year guidance of $310 to $320 million •FDA approval of LIVMARLI for cholestatic pruritus in PFIC patients achieved in March •Volixibat VISTAS and VANTAGE interim analyses scheduled for June of 2024 •Cash balance of

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commission

Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.

MIRUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY As Amended [ ], 2024, Effective as of [ ], 2024 Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Mirum Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Emplo

Offer Letter by and between the Registrant and Joanne Quan, dated January 11, 2024.

950 Tower Lane Suite 1050 Foster City, CA 94404 650-667-4085 www.mirumpharma.com January 11, 2024 Joanne Quan, MD […***…] Re: Employment Terms Dear Joanne, It is my pleasure to offer you employment with Mirum Pharmaceuticals, Inc. (the “Company”) on the terms set forth in this offer letter (this “Offer Letter”). We are building the premier rare liver disease company and are excited to have you as

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 00

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant  o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitt

As filed with the Securities and Exchange Commission on March 15, 2024

As filed with the Securities and Exchange Commission on March 15, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceu

Exhibit 4.3

Exhibit 4.3 DESCRIPTION OF COMMON STOCK General The following description summarizes the terms of the common stock of Mirum Pharmaceuticals, Inc., or we, our or us. Because it is only a summary, it does not contain all the information that may be important to you. For a complete description of the matters set forth in this “Description of Common Stock,” you should refer to our amended and restated

Office Lease, dated January 17, 2024, by and between the Registrant and Hudson Metro Center, LLC.

Office Lease METRO CENTER 989 EAST HILLSDALE BOULEVARD FOSTER CITY, CALIFORNIA Between HUDSON METRO CENTER, LLC, a Delaware limited liability company as Landlord, and MIRUM PHARMACEUTICALS, INC.

Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended.

Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the “Board”) who is not also serving as an employee of or consultant to Mirum Pharmaceuticals, Inc. (the “Company”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Non-Employee Director Compensation Policy for his or her

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirum Pharmaceuticals, Inc.

Third Amendment to Office Lease, dated January 17, 2024, by and between the Registrant and Hudson Metro Center, LLC.

THIRD AMENDMENT THIS THIRD AMENDMENT (this “Amendment”) is made and entered into as of January 17, 2024, by and between HUDSON METRO CENTER, LLC, a Delaware limited liability company (“Landlord”), and MIRUM PHARMACEUTICALS, INC.

Mirum Pharmaceuticals, Inc. 2020 Inducement plan, as amended August 24, 2023

Mirum Pharmaceuticals, Inc. 2020 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: March 18, 2020 Amended by the Compensation Committee of the Board of Directors: December 16, 2020 Amended by the Compensation Committee of the Board of Directors: November 18, 2021 Amended by the Compensation Committee of the Board of Directors: August 24, 2023 1. General. (a) Eligible

Mirum Pharmaceuticals Inc. Incentive Compensation Recoupment Policy.

MIRUM PHARMACEUTICALS, INC. Incentive Compensation Recoupment Policy 1. Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), has determined that it is in the best interests of the Company and its stockholders to adopt this Incentive Compensation Recoupment Policy (this

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Mirum Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2024 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update –Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142% growth over 2022 total revenue

Exhibit 99.1 Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Business Update –Net product sales totaled $178.9 million, and full year 2023 revenue totaled $186.4 million, delivering 142% growth over 2022 total revenue –2024 expected global net product sales of $310 million to $320 million –LIVMARLI PFIC PDUFA date on track for March 13, 2024 –Volixibat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):  ☒  Form 10-K  ☐  Form 20-F    ☐  Form 11-K  ☐  Form 10-Q ☐  Form 10-D  ☐  Form N-CEN  ☐  Form N-CSR For Period Ended: Decemb

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one):  ☒  Form 10-K  ☐  Form 20-F    ☐  Form 11-K  ☐  Form 10-Q ☐  Form 10-D  ☐  Form N-CEN  ☐  Form N-CSR For Period Ended: December 31, 2023 ☐  Transition Report on Form 10-K ☐  Transition Report on Form 20-F ☐  Transition Report on Form 11-K ☐  Transition Report on Form 10-Q Fo

MIRM / Mirum Pharmaceuticals, Inc. / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mirum Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate

MIRM / Mirum Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv01467-mirumpharmaceuticals.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Mirum Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 604749101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 Mirum Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2024 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Mirum Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commis

Established leader in the development and commercialization of life changing rare disease medicines Standard of Care Medicines Late-Stage Indications Countries with Reimbursed Access 3 4 18

EX-99.2 January 2024 Mirum Pharmaceuticals: Transforming Lives in Rare Disease Exhibit 99.2 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this pre

Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates

Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited 2023 Net Revenue and Provides Corporate Updates - $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89% year-over-year growth, preliminary and unaudited FOSTER CITY, Cal

MIRM / Mirum Pharmaceuticals, Inc. / New Enterprise Associates 16, L.P. - NEW ENTERPRISE ASSOCIATES 16, L.P. / MIRUM PHARMACEUTICALS, INC. -- SCHEDULE 13D/A(#2E) Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 604749101 (CUSIP Number) Stephanie Brecher New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 842-4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Mirum Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 18, 2023 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Comm

Sales Agreement by and between the Registrant, Leerink Partners LLC and Cantor Fitzgerald & Co., dated November 2, 2023 (incorporated by reference to Exhibit 10.3 to the Registrant’s Quarterly Report on Form 10-Q, filed with the SEC on November 2, 2023)

Exhibit 10.3 MIRUM PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT November 2, 2023 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Cantor Fitzgerald & Co. 110 East 59th Street New York, New York 10022 Ladies and Gentlemen: Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (th

Up to $200,000,000 Common Stock

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-267357 PROSPECTUS SUPPLEMENT (To Prospectus Dated September 9, 2022) Up to $200,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with Leerink Partners LLC, or Leerink Partners, and Cantor Fitzgerald & Co., or Cantor, relating to the sale of shares of our common stock offered by this prospect

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

Exhibit 99.5 UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION On August 31, 2023 (the “Closing Date”), Mirum Pharmaceuticals, Inc., a Delaware corporation, (the “Company”, “Mirum”) completed the purchase from Travere Therapeutics, Inc. (“Travere”) of substantially all of the assets of Travere that are primarily related to its business of development, manufacture (including synthesis, f

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of In

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38981 Mirum

BILE ACID BUSINESS OF TRAVERE THERAPEUTICS, INC. INDEX TO THE UNAUDITED COMBINED FINANCIAL STATEMENTS Page Unaudited Combined Balance Sheet at June 30, 2023 2 Unaudited Combined Statement of Operations for the six months ended June 30, 2023 3 Unaudit

Exhibit 99.3 BILE ACID BUSINESS OF TRAVERE THERAPEUTICS, INC. Combined Financial Statements as of and for the six months ended June 30, 2023 BILE ACID BUSINESS OF TRAVERE THERAPEUTICS, INC. INDEX TO THE UNAUDITED COMBINED FINANCIAL STATEMENTS Page Unaudited Combined Balance Sheet at June 30, 2023 2 Unaudited Combined Statement of Operations for the six months ended June 30, 2023 3 Unaudited Combin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commi

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirum Pharmaceuticals, Inc.

INDEX TO THE COMBINED FINANCIAL STATEMENTS Page Independent Auditor’s Report 3 Combined Balance Sheet at December 31, 2022 4 Combined Statement of Operations for the year ended December 31, 2022 5 Combined Statement of Net Parent Investment for the y

Exhibit 99.4 BILE ACID BUSINESS OF TRAVERE THERAPEUTICS, INC. Combined Financial Statements as of and for the year ended December 31, 2022 and Independent Auditor’s Report 1 INDEX TO THE COMBINED FINANCIAL STATEMENTS Page Independent Auditor’s Report 3 Combined Balance Sheet at December 31, 2022 4 Combined Statement of Operations for the year ended December 31, 2022 5 Combined Statement of Net Par

Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Third quarter 2023 total revenue of $47.7 million - Completed acquisition of CHENODAL® and CHOLBAM® - Announced positive Phase 3 RESTORE study results evaluating CHENODAL (chenodiol) in patients with CTX; NDA filing expected in H1 2024 - Conference call to provide business updates today,

As filed with the Securities and Exchange Commission on November 2, 2023

As filed with the Securities and Exchange Commission on November 2, 2023 Registration No.

Calculation of Filing Fee Tables (Form Type) Mirum Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule(1) Amount Registered Proposed

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Mirum Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Mirum Pharmaceut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commi

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Mirum Pharmaceuticals, Inc.

SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS

Exhibit 99.1 Unless the content otherwise requires, the terms “Mirum,” “company,” “our,” “us,” and “we” in this Exhibit 99.1 refer to Mirum Pharmaceuticals, Inc. SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS An investment in shares of our common stock involves a high degree of risk. Below is a list of the more significant risks associated with our business. This summary does not address all of the

As filed with the Securities and Exchange Commission on October 13, 2023

Table of Contents As filed with the Securities and Exchange Commission on October 13, 2023 Registration No.

Joint Filing Agreement

EX-99.1 2 ex991to13g07422mirm091823.htm JOINT FILING AGREEMENT Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated September 18, 2023 with respect to the shares of Common Stock, par value $0.0001 per share of Mirum Pharmaceuticals, Inc., a Delaware corporation, and any further amendments thereto executed by each and any of the undersigned shall

MIRM / Mirum Pharmaceuticals Inc / BIOTECHNOLOGY VALUE FUND L P - SCHEDULE 13G Passive Investment

SC 13G 1 sc13g07422mirm09182023.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Ti

Offer Letter by and between the Company and Eric Bjerkholt, dated August 8, 2023 (filed as Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on September 11, 2023, and incorporated by reference herein).

EX-10.1 Exhibit 10.1 950 Tower Lane Suite 1050 Foster City, CA 94404 650-667-4085 www.mirumpharma.com August 8, 2023 Eric Bjerkholt […***…] Re: Employment Terms Dear Eric, It is my pleasure to offer you employment with MIRUM PHARMACEUTICALS, INC. (the “Company”) on the terms set forth in this offer letter (this “Offer Letter”). We are building the premier rare liver disease company and are excited

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Mirum Pharmace

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Com

Page 2

EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of Common Stock of Mirum Pharmaceuticals, Inc. Date: September 5, 2023 FRAZIER LIFE SCIENCES IX, L.P. By FHMLS IX, L.P., its

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 MIRUM PHARMACEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 31, 2023 MIRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commis

Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics • Mirum has acquired Travere’s rights and assets related to Cholbam® and Chenodal® • Travere received $210 milli

Exhibit 99.1 Mirum Pharmaceuticals Completes Acquisition of Bile Acid Product Portfolio for Treatment of Rare Liver Diseases from Travere Therapeutics • Mirum has acquired Travere’s rights and assets related to Cholbam® and Chenodal® • Travere received $210 million at closing and is eligible for up to $235 million in potential sales-based milestone payments • Expands Mirum’s leadership in rare liv

MIRM / Mirum Pharmaceuticals Inc / Frazier Life Sciences IX, L.P. - SC 13D/A Activist Investment

SC 13D/A 1 d545032dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 604749 101 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Addr

Mirum Pharmaceuticals, Inc. Amended and Restated Severance Benefit Plan and form of Participation Agreement thereunder

Exhibit 10.1 MIRUM PHARMACEUTICALS, INC. SEVERANCE BENEFIT PLAN APPROVED BY THE BOARD OF DIRECTORS: NOVEMBER 30, 2018 AMENDED AND RESTATED: AUGUST 24, 2023 Section 1. INTRODUCTION. The Mirum Pharmaceuticals, Inc. Severance Benefit Plan (the “Plan”) is hereby amended and restated effective as of August 24, 2023 (the “Effective Date”). The purpose of the Plan is to provide for the payment of severan

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 24, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commis

Form of Subscription Agreement

Exhibit 10.1 Execution Version SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made and entered into as of July 16, 2023 (the “Effective Date”) by and among Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on the signature pages hereto, severally and not jointly (each a “Purchaser” and together the “Purchasers”). Certai

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38981 Mirum Pharm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Mirum Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update - $37.5 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $32.5 million, for second quarter 2023 - Acquiring CHENODAL® and CHOLBAM®, advancing Mirum’s leadership in pediatric hepatology with a multi-product franchise - Four late-stage clinical

Form of Registration Rights Agreement

EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [ ], 2023, among Mirum Pharmaceuticals, Inc., a Delaware corporation, and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). WHEREAS, the Company is party to that certain Asset Purchase Agreeme

Form of Subscription Agreement

EX-10.1 Exhibit 10.1 Execution Version SUBSCRIPTION AGREEMENT This Subscription Agreement (this “Agreement”) is made and entered into as of June 16, 2023 (the “Effective Date”) by and among Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the purchasers listed on the signature pages hereto, severally and not jointly (each a “Purchaser” and together the “Purchasers”)

Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements othe

EX-99.2 July 2023 Mirum Pharmaceuticals: Transforming Lives in Rare Disease Exhibit 99.2 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2023 MIRUM PHARMACEUTICA

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 16, 2023 MIRUM PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissi

Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics

EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Enters Agreement to Acquire Bile Acid Product Portfolio for the Treatment of Rare Liver Diseases from Travere Therapeutics • Mirum to acquire all of Travere’s rights and assets related to Cholbam® and Chenodal® • Travere to receive up to $445 million with $210 million upfront and up to $235 million in potential sales-based milestones • Mirum announces con

Asset Purchase Agreement, dated July 16, 2023, by and between Mirum Pharmaceuticals, Inc. and Travere Therapeutics, Inc. (incorporated by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on July 17, 2023).

EX-2.1 Exhibit 2.1 Execution Version CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. ASSET PURCHASE AGREEMENT by and between TRAVERE THERAPEUTICS, INC. and MIRUM PHARMACEUTICALS, INC. dated as of July 16, 2023 TABLE OF CONTENTS

MIRM / Mirum Pharmaceuticals Inc / New Enterprise Associates 16, L.P. - NEW ENTERPRISE ASSOCIATES 16, L.P. / MIRUM PHARMACEUTICALS, INC. -- SCHEDULE 13D/A(#1) Activist Investment

Schedule 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 604749101 (CUSIP Number) Louis S. Citron, Esq. New Enterprise Associates 1954 Greenspring Drive, Suite 600, Timonium, MD 21093 (410) 8

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Mirum Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 12, 2023 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissi

Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update - $31.6 million total revenue, including net product sales for LIVMARLI® (maralixibat) oral solution of $29.1 million, for first quarter 2023 - Conference call to provide business updates today, May 4 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif.-(BUSINESS WIRE)-May 4, 2023-Mirum Pharmac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38981 Mirum Phar

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Mirum Pharmaceuticals

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commission

MIRM / Mirum Pharmaceuticals Inc / Flynn James E Passive Investment

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering

EX-99.2 Exhibit 99.2 Mirum Pharmaceuticals Prices Upsized $275.0 Million Convertible Senior Notes Offering FOSTER CITY, Calif.—(BUSINESS WIRE)—April 12, 2023—Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced the pricing of its offering of $275.0 million aggregate principal amount of 4.00% convertible senior notes due 2029 (the “notes”) in a private offering to qualified institut

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Mirum Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering

EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Proposed Convertible Senior Notes Offering FOSTER CITY, Calif.—(BUSINESS WIRE)—April 12, 2023—Mirum Pharmaceuticals, Inc. (“Mirum”) (Nasdaq: MIRM) today announced its intention to offer, subject to market and other conditions, $200.0 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private offering to qu

Indenture, dated as of April 17, 2023, between Mirum Pharmaceuticals, Inc. and U.S. Bank Trust Company, National Association, as trustee (incorporated by reference to Exhibit 4.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on April 17, 2023).

EX-4.1 Exhibit 4.1 MIRUM PHARMACEUTICALS, INC. and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION as Trustee INDENTURE Dated as of April 17, 2023 4.00% Convertible Senior Notes due 2029 TABLE OF CONTENTS Page Article 1. Definitions; Rules of Construction 1 Section 1.01. Definitions 1 Section 1.02. Other Definitions 13 Section 1.03. Rules of Construction 14 Article 2. The Notes 15 Section 2.01. Form

Page 2

EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of Common Stock of Mirum Pharmaceuticals, Inc. Date: April 14, 2023 FRAZIER LIFE SCIENCES IX, L.P. By FHMLS IX, L.P., its ge

MIRM / Mirum Pharmaceuticals Inc / Frazier Life Sciences IX, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 604749 101 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of Pe

Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 12, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results

EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited First Quarter 2023 Financial Results FOSTER CITY, Calif – April 12, 2023 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced estimated revenue, including net product sales, and cash balance for the first quarter 2023. The company’s preliminary unaudited financial results for the first quarter of 2023 include: • App

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 5, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commissi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Mirum Pharmaceutic

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

Filing Fee Table

EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirum Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on March 9, 2023

S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Mirum Pharmaceutica

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 8, 2023 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commissi

Subsidiaries of the Registrant

Exhibit 21.1 Subsidiaries of the Registrant Mirum Pharmaceuticals AG, a company formed in Switzerland Mirum Pharmaceuticals International B.V., a company formed in the Netherlands

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI® (maralixibat) oral solution totaled $75.1 million for first full fiscal year of U.S. commercial launch, and full year 2022 revenue totaled $77.1 million - Conference call to provide business updates today, March 8 at 1:30 p.m. PT/4:30 p.m. ET

Mirum Pharmaceuticals, Inc. 2020 Inducement Plan

Exhibit 10.11 Mirum Pharmaceuticals, Inc. 2020 Inducement Plan Adopted by the Compensation Committee of the Board of Directors: March 18, 2020 Amended by the Compensation Committee of the Board of Directors: December 16, 2020 Amended by the Compensation Committee of the Board of Directors: November 18, 2021 1. General. (a) Eligible Award Recipients. The only persons eligible to receive grants of A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceu

MIRM / Mirum Pharmaceuticals Inc / Rock Springs Capital Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

MIRM / Mirum Pharmaceuticals Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G Passive Investment

SC 13G 1 mirumpharmaceuticals13g.htm SC 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Mirum Pharmaceuticals, Inc. (Name of Issuer – as specified in its charter) Common stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) December 31, 2022 (Date of Event which Requires Fili

MIRM / Mirum Pharmaceuticals Inc / Flynn James E Passive Investment

SC 13G/A 1 e618234sc13ga-mirum.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 4) * Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 604749101 (CUSIP Number) Decemb

Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates - $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited - sNDA for LI

Exhibit 99.1 Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates - $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited - sNDA for LIVMARLI in PFIC submission planned for first quarter 2023 - Multiple data analyses planned in 2023 advancing late-stage cholestasis progra

Transition, Separation and Consulting Agreement, dated January 7, 2023, by and between the Registrant and Ian Clements, Ph.D.

Exhibit 10.1 January 7, 2023 Ian Clements, Ph.D. Re: Transition, Separation and Consulting Agreement Dear Ian: This letter sets forth the substance of the transition, separation and consulting agreement (the “Agreement”) that Mirum Pharmaceuticals, Inc. (the “Company”) is offering to you. 1. Separation. Your last day of work with the Company and your employment termination date will be May 15, 202

LIVMARLI approved for cholestatic pruritus In Alagille Syndrome Robust Pipeline Strong Team and Balance Sheet Leading the Way in Rare Diseases Delivering remarkable treatments to patients in need worldwide

January 2023 Corporate Presentation Exhibit 99.2 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2023 Mirum Pharmaceuti

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2023 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commis

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Mirum Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

MIRM / Mirum Pharmaceuticals Inc / RiverVest Venture Fund IV, L.P. - SC 13D/A Activist Investment

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Mirum Pharmaceu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 29, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commi

Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI? (maralixibat) oral solution totaled $18.8 million in the third quarter of 2022 and $47.2 million year-to-date - Mirum raises 2022 full year net product sales guidance estimate for LIVMARLI to $70 million - Conference call to provide business updates today,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum

Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements othe

MARCH-PFIC Phase 3 Topline Results October 24, 2022 Exhibit 99.2 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management?s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including inform

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 24, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commi

Positive Topline Data Announced from Mirum’s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC)

Exhibit 99.1 Positive Topline Data Announced from Mirum?s LIVMARLI Phase 3 MARCH Study in Progressive Familial Intrahepatic Cholestasis (PFIC) ? Met primary endpoint (p=0.0098); highly statistically significant effects in all PFIC subtypes. ? Significant improvements in total bilirubin and growth versus placebo at six months. ? Mirum plans to submit these data to regulatory agencies. ? Mirum to ho

MIRM / Mirum Pharmaceuticals Inc / Flynn James E Passive Investment

SC 13G/A 1 e621920sc13ga-mirum.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3) * Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 604749101 (CUSIP Number) Septem

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.8 MIRUM PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF MIRUM PHARMACEUTICALS, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT THIS DEBT SECURITIES WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MIRUM PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga

Form of Common Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.6 MIRUM PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF MIRUM PHARMACEUTICALS, INC. FORM OF COMMON STOCK WARRANT AGREEMENT THIS COMMON STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MIRUM PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] organized and

Filing Fee Table.

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Mirum Pharmaceuticals, Inc.

As filed with the Securities and Exchange Commission on September 9, 2022

S-3ASR 1 d400562ds3asr.htm S-3ASR Table of Contents As filed with the Securities and Exchange Commission on September 9, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 83-1281555 (State or ot

Form of Preferred Stock Warrant Agreement and Warrant Certificate.

Exhibit 4.7 MIRUM PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF MIRUM PHARMACEUTICALS, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT THIS PREFERRED STOCK WARRANT AGREEMENT (this ?Agreement?), dated as of [?], between MIRUM PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), and [?], a [corporation] [national banking association] orga

Form of Indenture, by and between the Registrant and one or more trustees to be named.

EX-4.3 Exhibit 4.3 MIRUM PHARMACEUTICALS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [•], 20 Debt Securities TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 5 Section 2.01 Designation and Terms of Securities 5 Section 2.02 Form of Securities and Trustee’s Certif

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

MIRM / Mirum Pharmaceuticals Inc / Novo Holdings A/S - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy

MIRM / Mirum Pharmaceuticals Inc / Frazier Life Sciences IX, L.P. - SC 13D/A Activist Investment

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 604749 101 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of Pe

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commiss

Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, SVB Securities LLC and Evercore Group L.L.C., dated August 9, 2022.

EX-1.1 2 d376155dex11.htm EX-1.1 Exhibit 1.1 Execution Verison Mirum Pharmaceuticals, Inc. 3,478,261 Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York August 9, 2022 J.P. Morgan Securities LLC SVB Securities LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10017 c/o SVB Secu

Joint book-running managers J.P. Morgan SVB Securities Evercore ISI Lead manager Raymond James

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-240290 Prospectus Supplement (To prospectus dated August 12, 2020) 3,478,261 shares Common stock We are offering 3,478,261 shares of our common stock. Our common stock is listed on the Nasdaq Global Market under the symbol ?MIRM.? On August 9, 2022, the last reported sale price for our common stock on the Nasdaq Global Market

Joint book-running managers J.P. Morgan SVB Securities Evercore ISI Lead manager Raymond James

Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.

Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update - Net product sales for LIVMARLI? (maralixibat) oral solution totaled $17.5 million in the second quarter of 2022 and $28.4 million year-to-date - Conference call to provide business updates today, August 4 at 1:30 p.m. PT/4:30 p.m. ET FOSTER CITY, Calif.-(BUSINESS WIRE)-August 4, 2022-Mir

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum Phar

MIRM / Mirum Pharmaceuticals Inc / Novo Holdings A/S - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Sh

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2022 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissio

Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors

Exhibit 99.1 Mirum Pharmaceuticals Appoints Saira Ramasastry to Board of Directors FOSTER CITY, Calif. ? June 6, 2022 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Saira Ramasastry to the Company?s board of directors and as a member of the audit committee where she will bring to bear her more than 20 years of financial leadership. ?Saira?s extensive financial and

Mirum Pharmaceuticals, Inc. 950 Tower Lane, Suite 1050 Foster City, CA 94404

Mirum Pharmaceuticals, Inc. 950 Tower Lane, Suite 1050 Foster City, CA 94404 June 6, 2022 VIA EDGAR Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz RE: Mirum Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed May 25, 2022 File No. 333-265210 Ladies and Gentlemen: Pursuant to Rule 461 under the Sec

Filing Fee Table

EX-FILING FEES 4 d349919dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Mirum Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Max

As filed with the Securities and Exchange Commission on May 25, 2022

Table of Contents As filed with the Securities and Exchange Commission on May 25, 2022 Registration No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 20, 2022 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissio

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum Pha

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commission

Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

Exhibit 99.1 Mirum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update - Total revenue for the first quarter of 2022 was $12.9 million including net product revenue for LIVMARLI? (maralixibat) oral solution of $10.9 million. - Conference call to provide business updates today, May 5 at 5:30 a.m. PT/8:30 a.m. ET FOSTER CITY, Calif.-(BUSINESS WIRE)-May 5, 2022-M

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Schedule 14A

TABLE OF CONTENTS SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

MIRM / Mirum Pharmaceuticals Inc / Novo Holdings A/S - SC 13D/A Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Sh

Forms of international grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan

Exhibit 10.6 MIRUM PHARMACEUTICALS, INC. STANDARD STOCK OPTION GRANT NOTICE - INTERNATIONAL (2019 EQUITY INCENTIVE PLAN) Mirum Pharmaceuticals, Inc. (the "Company"), pursuant to its 2019 Equity Incentive Plan (the "Plan"), hereby grants to Optionholder an option to purchase the number of shares of the Company's Common Stock set forth below. This option is subject to all of the terms and conditions

Forms of international restricted stock unit grant notice and award agreement under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan

Exhibit 10.8 International Mirum Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice - International (2019 Equity Incentive Plan) Mirum Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2019 Equity Incentive Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?

Mirum Pharmaceuticals, Inc. 2019 Employee Stock Purchase Plan Terms and conditions – Non-U.S. Participants

Exhibit 10.10 Mirum Pharmaceuticals, Inc. 2021 Employee Stock Purchase Plan Terms and Conditions ? Non-US Participants By enrolling in the 2019 Employee Stock Purchase Plan (the ?Plan?) through an online enrollment procedure or such other enrollment procedure as may be established by the Company or by a third party designated by the Company, the Participant agrees to the terms and conditions of th

Filing Fee Table

EX-FILING FEES 4 d318573dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Mirum Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rat

Mirum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended March 18, 2020

Exhibit 10.35 MIRUM PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Mirum Pharmaceuticals, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Policy f

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceu

Forms of international restricted stock unit grant notice and award agreement under the Mirum Pharmaceuticals, Inc. 2020 Inducement Plan (filed as Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K, filed with the Commission on March 9, 2022).

Exhibit 10.15 International Mirum Pharmaceuticals, Inc. Restricted Stock Unit Grant Notice - International (2020 Inducement Plan) Mirum Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2020 Inducement Plan (the ?Plan?), hereby awards to Participant a Restricted Stock Unit Award for the number of shares of the Company?s Common Stock (?Restricted Stock Units?) set forth below (the ?Award?). Th

Forms of international director grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2019 Equity Incentive Plan

Exhibit 10.7 International - director Mirum Pharmaceuticals, Inc. Director Stock Option Grant Notice - International (2019 Equity Incentive Plan) Mirum Pharmaceuticals, Inc. (the "Company"), pursuant to its 2019 Equity Incentive Plan (the "Plan"), hereby grants to Optionholder an option to purchase the number of shares of the Company's Common Stock set forth below. This option is subject to all of

Forms of international grant notice, stock option agreement and notice of exercise under the Mirum Pharmaceuticals, Inc. 2020 Inducement Plan

Exhibit 10.14 MIRUM PHARMACEUTICALS, INC. STOCK OPTION GRANT NOTICE - INTERNATIONAL (2020 INDUCEMENT PLAN) Mirum Pharmaceuticals, Inc. (the ?Company?), pursuant to its 2020 Inducement Plan (the ?Plan?), hereby grants to Optionholder an option to purchase the number of shares of the Company?s Common Stock set forth below. This option is subject to all of the terms and conditions as set forth in thi

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2022 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commiss

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update - Strong commercial launch underway with LIVMARLI® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of

Exhibit 99.1 Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2021 Financial Results and Provides Business Update - Strong commercial launch underway with LIVMARLI® (maralixibat) oral solution; net product revenue of $3.1 million for the first quarter of launch, total 2021 company revenue of $19.1 million - Expect at least $8.0 million in LIVMARLI net product sales in first quarter 2022 -

As filed with the Securities and Exchange Commission on March 9, 2022

As filed with the Securities and Exchange Commission on March 9, 2022 Registration No.

MIRM / Mirum Pharmaceuticals Inc / Rock Springs Capital Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

MIRM / Mirum Pharmaceuticals Inc / Flynn James E Passive Investment

SC 13G/A 1 e621289sc13ga-mirum.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2) * Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 604749101 (CUSIP Number) Decemb

LIVMARLI FDA-approved for cholestatic pruritus in Alagille Syndrome Robust Pipeline Strong Team and Balance Sheet Leading the Way in Rare Diseases Delivering remarkable treatments to patients in need worldwide $500M+ potential in ALGS in US 5 late-st

January 2022 Corporate Presentation Exhibit 99.2 Forward-Looking Statements This presentation contains "forward-looking" statements that are based on our management?s beliefs and assumptions and on information currently available to management. Forward-looking statements include all statements other than statements of historical fact contained in this presentation, including information concerning

Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones

Exhibit 99.1 Mirum Pharmaceuticals Provides Business Update and Highlights Key 2022 Corporate Milestones ? Unaudited estimated total LIVMARLI net product revenue of $3.0 million for fourth quarter 2021. ? Preliminary cash, cash equivalents, and short-term investments of $261.5 million as of December 31, 2021. FOSTER CITY, CA ? January 11, 2022 ? Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today pro

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2022 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commi

Completion of Acquisition or Disposition of Assets

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Comm

Asset Purchase Agreement, dated November 16, 2021, by and between the Registrant and Janssen Biotech, Inc.

Exhibit 10.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN JANSSEN BIOTECH, INC. AND MIRUM PHARMACEUTICALS, INC. November 16, 2021 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 1 1.1 Certain Definitions 1 ARTICLE 2 PURCHASE AND SALE; CLOSING 5 2.1 Purchase and Sale of Purchased Assets 5 2.2 Purchase Price 5 2.3 Closing 5 2.4 Title Passage; Delivery of Purchased Assets 5 2.5 Closing Deliveries by Seller 5 2.6

Entry into a Material Definitive Agreement, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Comm

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum

Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - U.S. commercial launch underway following U.S. FDA approval of LIVMARLITM (maralixibat) oral solution - Six-year analysis showing significant improvemen

Exhibit 99.1 Mirum Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update - U.S. commercial launch underway following U.S. FDA approval of LIVMARLITM (maralixibat) oral solution - Six-year analysis showing significant improvement in event-free survival with LIVMARLI compared to natural history cohort (p<0.0001) presented as late-breaking, Best of The Liver Meetin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 15, 2021 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Comm

Identification of the subsidiary which acquired the security being reported on by the parent holding company

Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. The reported securities are beneficially owned by Takeda Pharmaceuticals U.S.A., Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (72.70%) and Takeda Pharmaceuticals International AG (27.30%). Takeda Pharmaceuticals International AG is a direct, whol

Joint Filing Agreement

Exhibit 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Mirum Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(d) under the Securities Exchange Act of 1934, as amended, on behalf of each of t

MIRM / Mirum Pharmaceuticals Inc / TAKEDA PHARMACEUTICAL CO LTD - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* MIRUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) October 19, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

Amendment No. 1 to Revenue Interest Purchase Agreement, dated September 28, 2021, by and among the Registrant, Mulholland SA LLC and the Purchasers (incorporated by reference to Exhibit 10.1 to the Registrant’s Current Report on Form 8-K, filed with the SEC on September 29, 2021).

EX-10.1 2 d234534dex101.htm EX-10.1 Exhibit 10.1 Execution Version AMENDMENT NO. 1 TO REVENUE INTEREST PURCHASE AGREEMENT This Amendment No. 1 (this “Amendment”) is entered into by and among Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), Mulholland SA LLC, as Purchaser Agent for the Purchasers (in such capacity, the “Purchaser Agent”) and the Purchasers party to that certain

U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older - Mirum to host an investor call on September 29, 2021 at 4:30 p

Exhibit 99.1 U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and Older - Mirum to host an investor call on September 29, 2021 at 4:30 p.m. ET FOSTER CITY, Calif. ? September 29, 2021 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leader in rare liver disease, today annou

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Com

MIRM / Mirum Pharmaceuticals Inc / Novo Holdings A/S - AMENDMENT NO 3 TO SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Shayne Ken

Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors

EX-99.1 2 d216866dex991.htm EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of Directors FOSTER CITY, Calif. – August 19, 2021 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of industry veteran William C. Fairey to its Board of Directors. Mr. Fairey brings to Mirum significant experience in establishing commer

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commis

Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

EX-99.1 2 mirm-20210805ex991.htm EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update - NDA for maralixibat for cholestatic pruritus in Alagille syndrome under priority review; PDUFA date is September 29, 2021 - Commercial preparations complete in anticipation of U.S. launch of maralixibat in ALGS - Conference call to provide busines

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum Phar

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2021 Mirum Pharmaceuticals, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-38981 83-1281555 (State or Other Jurisdiction of Incorporation) (Commis

Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors

EX-99.1 2 d145739dex991.htm EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D. to Board of Directors FOSTER CITY, Calif. – June 7, 2021 - Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Carol L. Brosgart, M.D., clinical professor of medicine, biostatistics and epidemiology, University of California, San Francisc

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissio

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum Pha

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commission

Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update

EX-99.1 2 mirm-ex9916.htm EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update - NDA for maralixibat in Alagille syndrome (ALGS) granted priority review by U.S. FDA; PDUFA date is September 29, 2021 - Received additional $65.0 million in funding from Oberland Capital based on NDA acceptance - Commercial team hired in anticipation of U

- DEF 14A

Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

- DEFA14A

SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commiss

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38981 Mirum Pharmaceu

Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates

EX-99.1 2 mirm-ex9916.htm EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Results and Provides Business Updates - U.S. launch of maralixibat for Alagille syndrome (ALGS) planned for second half of 2021, if approved by FDA - Phase 2b programs initiated in Primary Sclerosing Cholangitis, Intrahepatic Cholestasis of Pregnancy and Biliary Atresia - Financial runway

Offer Letter by and between the Registrant and Peter Radovich, dated April 28, 2020.

Exhibit 10.18 Mirum Pharmaceuticals, Inc. April 8, 2020 Peter Radovich San Mateo, California Re:Employment Terms Dear Peter: It is my pleasure to offer you employment with Mirum Pharmaceuticals, Inc. (the ?Company?) on the terms set forth in this offer letter. We are building the premier rare liver disease company and are excited to have you as part of the team. The terms of the offer are as follo

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commissi

- S-8

As filed with the Securities and Exchange Commission on March 9, 2021 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mirum Pharmaceuticals, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

Joint Filing Agreement

EX-99.2 3 exhibit992-012721.htm EX-99.2 Exhibit 99.2 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Common Stock of Mirum Pharmaceuticals, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(d) under the Securities Exchange Act of

Identification of the subsidiary which acquired the security being reported on by the parent holding company

EX-99.1 2 exhibit991-012721.htm EX-99.1 Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company. The reported securities are beneficially owned by Takeda Pharmaceuticals U.S.A., Inc., which is a direct subsidiary of Takeda Pharmaceutical Company Limited (70.9%), Takeda Pharmaceuticals International AG (27.3%), and Shire Ireland Inve

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MIRUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* MIRUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat

Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2021 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (C

Mirum Pharmaceuticals Provides Corporate Update - Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021 - Launching volixibat

EX-99.1 2 d945260dex991.htm EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Provides Corporate Update - Completion of maralixibat rolling NDA targeted for Q1 2021 - Expecting first-patient-in for volixibat studies in ICP and PSC, and maralixibat study in biliary atresia in Q1 2021 - Launching volixibat primary biliary cholangitis program in H2 2021 - European commercial leader hired in anticipation of

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1) MIRUM PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) (

SC 13D/A SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class o

SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 604749101 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) (CUSIP Number)

SC 13D/A 1 d20043dsc13da.htm SC 13D - AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Mirum Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 604749 101 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Seattle, WA

Joint book-running managers J.P. Morgan SVB Leerink Evercore ISI Lead manager H.C. Wainwright & Co.

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-240290 Prospectus Supplement (To prospectus dated August 12, 2020) 3,750,000 shares Common stock We are offering 3,750,000 shares of our common stock. Our common stock is listed on The Nasdaq Global Market under the symbol “MIRM.” On December 11, 2020, the last reported sale price for our common stock on The Nasdaq Globa

Underwriting Agreement by and among the Company, J.P. Morgan Securities LLC, SVB Leerink LLC and Evercore Group L.L.C., dated December 14, 2020.

EX-1.1 Exhibit 1.1 Execution Version Mirum Pharmaceuticals, Inc. 3,750,000 Shares Common Stock ($0.0001 par value) Underwriting Agreement New York, New York December 14, 2020 J.P. Morgan Securities LLC SVB Leerink LLC Evercore Group L.L.C. As Representatives of the several Underwriters c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10017 c/o SVB Leerink LLC One Federal Street

Financial Statements and Exhibits, Other Events - 8-K

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2020 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (

Joint book-running managers J.P. Morgan SVB Leerink Evercore ISI Lead manager H.C. Wainwright & Co.

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-240290 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2020 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commi

MIRUM PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT

EX-99.2 3 mirm-ex9929.htm EX-99.2 Exhibit 99.2 MIRUM PHARMACEUTICALS, INC. COMMON STOCK PURCHASE AGREEMENT THIS COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of December 8, 2020 (the “Execution Date”) by and among Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the investors listed on Annex I hereto, each a Delaware limited partnership, and their affiliates

REVENUE INTEREST PURCHASE AGREEMENT dated as of December 8, 2020 MIRUM PHARMACEUTICALS, INC., the Purchasers from time to time party hereto MULHOLLAND SA LLC, as Purchaser Agent TABLE OF CONTENTS

EX-99.1 2 mirm-ex99111.htm EX-99.1 Exhibit 99.1 Certain information in this document identified by brackets has been omitted because it is both not material and would be competitively harmful if publicly disclosed. Execution Version REVENUE INTEREST PURCHASE AGREEMENT dated as of December 8, 2020 among MIRUM PHARMACEUTICALS, INC., the Purchasers from time to time party hereto and MULHOLLAND SA LLC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum

Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day

Exhibit 99.1 Mirum Pharmaceuticals Provides Third Quarter 2020 Financial Results and Business Update, and Announces Virtual Investor Day - Initiated rolling NDA submission and launched Expanded Access Program for maralixibat in Alagille syndrome. - Presented five-year transplant-free survival data for patients with PFIC2 at Digital International Liver Congress (EASL). - European Marketing Authoriz

Financial Statements and Exhibits, Results of Operations and Financial Condition

8-K 1 mirm-8k20201112.htm 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2020 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisd

As filed with the Securities and Exchange Commission on August 10, 2020

As filed with the Securities and Exchange Commission on August 10, 2020 Registration No.

Mirum Pharmaceuticals, INC. 950 Tower Lane, Suite 1050 Foster City, California 94404

Mirum Pharmaceuticals, INC. 950 Tower Lane, Suite 1050 Foster City, California 94404 August 10, 2020 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz Re:Mirum Pharmaceuticals, Inc. Registration Statement on Form S-3, as amended (File No. 333-240290) Request for Acceleration of Effective Date Dear Ms.

Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates

EX-99.1 2 mirm-ex9916.htm EX-99.1 Exhibit 99.1 Mirum Pharmaceuticals Announces Second Quarter 2020 Financial Results and Provides Clinical Program Updates - Rolling NDA submission for maralixibat in Alagille syndrome (ALGS) to be initiated in third quarter 2020; planning for potential launch in second half of 2021. - Submission of European marketing authorization application for maralixibat in PFI

Quarterly Report - 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38981 Mirum Phar

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2020 Mirum Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38981 83-1281555 (State or other jurisdiction of incorporation) (Commiss

Form of Preferred Stock Warrant Agreement and Warrant Certificate

Exhibit 4.7 Mirum Pharmaceuticals, Inc. and , As Warrant Agent Form of Preferred Stock Warrant Agreement Dated as of Mirum Pharmaceuticals, INC. FORM OF PREFERRED STOCK WARRANT AGREEMENT This Preferred Stock Warrant Agreement (this “Agreement”), dated as of [●], between Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] orga

Form of Debt Securities Warrant Agreement and Warrant Certificate.

Exhibit 4.8 Mirum Pharmaceuticals, Inc. and , As Warrant Agent Form of Debt Securities Warrant Agreement Dated as of Mirum Pharmaceuticals, INC. FORM OF DEBT SECURITIES WARRANT AGREEMENT This Debt Securities Warrant Agreement (this “Agreement”), dated as of [●], between Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [●], a [corporation] [national banking association] orga

Sales Agreement by and between the Registrant and SVB Leerink LLC, dated August 3, 2020 (incorporated by reference to Exhibit 1.2 to the Registrant’s Registration Statement on Form S-3, as amended (File No. 333-240290), filed with the SEC on August 3, 2020, and incorporated by reference herein).

Exhibit 1.2 MIRUM PHARMACEUTICALS, INC. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT August 3, 2020 SVB LEERINK LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Mirum Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with SVB Leerink LLC (the “Agent”), as follows: 1.Issuance and